{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:50:11Z","timestamp":1784811011590,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014840","name":"Gemeinsame Bundesausschuss","doi-asserted-by":"publisher","award":["01VSF19022"],"award-info":[{"award-number":["01VSF19022"]}],"id":[{"id":"10.13039\/501100014840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Choosing an antipsychotic medication is an important medical decision in the treatment of schizophrenia. This decision requires risk-benefit assessments of antipsychotics, and thus, shared-decision making between physician and patients is strongly encouraged. Although the efficacy and side-effect profiles of antipsychotics are well-established, there is no clear framework for the communication of the evidence between physicians and patients. For this reason, we developed an evidence-based shared-decision making assistant (SDM-assistant) that presents high-quality evidence from network meta-analysis on the efficacy and side-effect profile of antipsychotics and can be used as a basis for shared-decision making between physicians and patients when selecting antipsychotic medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The planned matched-pair cluster-randomised trial will be conducted in acute psychiatric wards (<jats:italic>n<\/jats:italic>\u2009=\u200914 wards planned) and will include adult inpatients with schizophrenia or schizophrenia-like disorders (<jats:italic>N<\/jats:italic>\u2009=\u2009252 participants planned). On the intervention wards, patients and their treating physicians will use the SDM-assistant, whenever a decision on choosing an antipsychotic is warranted. On the control wards, antipsychotics will be chosen according to treatment-as-usual. The primary outcome will be patients\u2019 perceived involvement in the decision-making during the inpatient stay as measured with the SDM-Q-9. We will also assess therapeutic alliance, symptom severity, side-effects, treatment satisfaction, adherence, quality of life, functioning and rehospitalizations as secondary outcomes. Outcomes could be analysed at discharge and at follow-up after three months from discharge. The analysis will be conducted per-protocol using mixed-effects linear regression models for continuous outcomes and logistic regression models using generalised estimating equations for dichotomous outcomes. Barriers and facilitators in the implementation of the intervention will also be examined using a qualitative content analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is the first trial to examine a decision assistant specifically designed to facilitate shared-decision making for choosing antipsychotic medications, i.e., SDM-assistant, in acutely ill inpatients with schizophrenia. If the intervention can be successfully implemented, SDM-assistant could advance evidence-based medicine in schizophrenia by putting medical evidence on antipsychotics into the context of patient preferences and values. This could subsequently lead to a higher involvement of the patients in decision-making and better therapy decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>German Clinical Trials Register (ID: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00027316\">DRKS00027316<\/jats:ext-link>, registration date 26.01.2022).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04036-5","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:26:36Z","timestamp":1655465196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bursch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Matthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00fchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"10202","key":"4036_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"2\u20133","key":"4036_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2009.06.008","volume":"113","author":"M Edlinger","year":"2009","unstructured":"Edlinger M, Hofer A, Rettenbacher MA, Baumgartner S, Widschwendter CG, Kemmler G, et al. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res. 2009;113(2\u20133):246\u201351.","journal-title":"Schizophr Res"},{"issue":"1","key":"4036_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","volume":"18","author":"E Achtyes","year":"2018","unstructured":"Achtyes E, Simmons A, Skabeev A, Levy N, Jiang Y, Marcy P, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18(1):292.","journal-title":"BMC Psychiatry"},{"key":"4036_CR4","doi-asserted-by":"crossref","unstructured":"Gaebel W, Hasan A, Falkai P, editors. S3-Leitlinie Schizophrenie. Springer-Verlag; 2019. https:\/\/link.springer.com\/book\/10.1007\/978-3-662-59380-6.","DOI":"10.1007\/978-3-662-59380-6"},{"issue":"2","key":"4036_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/S1461145710001380","volume":"14","author":"S Leucht","year":"2011","unstructured":"Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269\u201384.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"4036_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7326\/0003-4819-140-1-200401060-00012","volume":"140","author":"SN Whitney","year":"2004","unstructured":"Whitney SN, McGuire AL, McCullough LB. A typology of shared decision making, informed consent, and simple consent. Ann Intern Med. 2004;140(1):54\u20139.","journal-title":"Ann Intern Med"},{"issue":"9898","key":"4036_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(13)61215-5","volume":"382","author":"JD Birkmeyer","year":"2013","unstructured":"Birkmeyer JD, Reames BN, McCulloch P, Carr AJ, Campbell WB, Wennberg JE. Understanding of regional variation in the use of surgery. Lancet. 2013;382(9898):1121\u20139.","journal-title":"Lancet."},{"issue":"5","key":"4036_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1176\/ps.2006.57.5.700","volume":"57","author":"J Hamann","year":"2006","unstructured":"Hamann J, Adjan S, Leucht S, Kissling W. Psychiatric decision making in the adoption of a new antipsychotic in Germany. Psychiatr Serv. 2006;57(5):700\u20133.","journal-title":"Psychiatr Serv"},{"issue":"7","key":"4036_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/appi.ajp.161.7.1301","volume":"161","author":"J Hamann","year":"2004","unstructured":"Hamann J, Langer B, Leucht S, Busch R, Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry. 2004;161(7):1301\u20134.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4036_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.euroneuro.2010.01.001","volume":"20","author":"J Hamann","year":"2010","unstructured":"Hamann J, Mendel R, Heres S, Leucht S, Kissling W. How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol. 2010;20(4):276\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"4036_CR11","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1017\/S0033291711000808","volume":"41","author":"R Mendel","year":"2011","unstructured":"Mendel R, Traut-Mattausch E, Jonas E, Leucht S, Kane JM, Maino K, et al. Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses. Psychol Med. 2011;41(12):2651\u20139.","journal-title":"Psychol Med"},{"issue":"2","key":"4036_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.eurpsy.2010.09.004","volume":"26","author":"J Hamann","year":"2011","unstructured":"Hamann J, Mendel R, B\u00fchner M, Leucht S, Kissling W. Drowning in numbers-what psychiatrists mean when talking to patients about probabilities of risks and benefits of medication. Eur Psychiatry. 2011;26(2):130\u20131.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"4036_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00127-015-1089-z","volume":"51","author":"J Hamann","year":"2016","unstructured":"Hamann J, Kohl S, McCabe R, B\u00fchner M, Mendel R, Albus M, et al. What can patients do to facilitate shared decision making? A qualitative study of patients with depression or schizophrenia and psychiatrists. Soc Psychiatry Psychiatr Epidemiol. 2016;51(4):617\u201325.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"4","key":"4036_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/NMD.0b013e31816a62a0","volume":"196","author":"J Hamann","year":"2008","unstructured":"Hamann J, Mendel RT, Fink B, Pfeiffer H, Cohen R, Kissling W. Patients' and psychiatrists' perceptions of clinical decisions during schizophrenia treatment. J Nerv Ment Dis. 2008;196(4):329\u201332.","journal-title":"J Nerv Ment Dis"},{"key":"4036_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","volume":"5","author":"PM Haddad","year":"2014","unstructured":"Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43\u201362.","journal-title":"Patient Relat Outcome Meas"},{"key":"4036_CR16","volume-title":"How should patient decision aids for schizophrenia treatment be designed? - a scoping review. under review","author":"F Schuster","year":"2022","unstructured":"Schuster F, M\u00fcller K, Rodoligco A, Siafis S, Leucht S, Hamann J. How should patient decision aids for schizophrenia treatment be designed? - a scoping review. under review; 2022."},{"issue":"4","key":"4036_CR17","first-page":"CD001431-CD","volume":"4","author":"D Stacey","year":"2017","unstructured":"Stacey D, L\u00e9gar\u00e9 F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4(4):CD001431-CD.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"4036_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1600-0447.2006.00798.x","volume":"114","author":"J Hamann","year":"2006","unstructured":"Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand. 2006;114(4):265\u201373.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"4036_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12888-017-1240-3","volume":"17","author":"J Hamann","year":"2017","unstructured":"Hamann J, Holzh\u00fcter F, Stecher L, Heres S. Shared decision making PLUS - a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS). BMC Psychiatry. 2017;17(1):78.","journal-title":"BMC Psychiatry."},{"issue":"3","key":"4036_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"5","key":"4036_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/bmjqs-2017-006986","volume":"27","author":"KR Sepucha","year":"2018","unstructured":"Sepucha KR, Abhyankar P, Hoffman AS, Bekker HL, LeBlanc A, Levin CA, et al. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. BMJ Qual Saf. 2018;27(5):380\u20138.","journal-title":"BMJ Qual Saf"},{"issue":"6","key":"4036_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/0272989X13501721","volume":"34","author":"N Joseph-Williams","year":"2014","unstructured":"Joseph-Williams N, Newcombe R, Politi M, Durand MA, Sivell S, Stacey D, et al. Toward minimum standards for certifying patient decision aids: a modified delphi consensus process. Med Decis Mak. 2014;34(6):699\u2013710.","journal-title":"Med Decis Mak"},{"key":"4036_CR23","doi-asserted-by":"publisher","first-page":"j4891","DOI":"10.1136\/bmj.j4891","volume":"359","author":"G Elwyn","year":"2017","unstructured":"Elwyn G, Durand MA, Song J, Aarts J, Barr PJ, Berger Z, et al. A three-talk model for shared decision making: multistage consultation process. Bmj. 2017;359:j4891.","journal-title":"Bmj."},{"issue":"1","key":"4036_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00406-021-01378-1","volume":"272","author":"S Leucht","year":"2022","unstructured":"Leucht S, Davis JM. Which first-generation antipsychotics should be \u201crepurposed\u201d for the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):1\u20133.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"4036_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","volume":"266","author":"S Leucht","year":"2016","unstructured":"Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266(6):477\u201380.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"4036_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.psyneuen.2008.02.008","volume":"33","author":"H Knegtering","year":"2008","unstructured":"Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33(6):711\u20137.","journal-title":"Psychoneuroendocrinology."},{"issue":"3","key":"4036_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","volume":"26","author":"A Serretti","year":"2011","unstructured":"Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130\u201340.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"4036_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1503\/cmaj.150430","volume":"188","author":"BC Johnston","year":"2016","unstructured":"Johnston BC, Alonso-Coello P, Friedrich JO, Mustafa RA, Tikkinen KAO, Neumann I, et al. Do clinicians understand the size of treatment effects? A randomized survey across 8 countries. CMAJ. 2016;188(1):25\u201332.","journal-title":"CMAJ."},{"key":"4036_CR29","doi-asserted-by":"crossref","unstructured":"Leucht S, Siafis S, Engel RR, Schneider-Thoma J, Bighelli I, Cipriani A, et al. How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. Schizophr Bull. 2021.","DOI":"10.1093\/schbul\/sbab094"},{"issue":"1\u20133","key":"4036_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2010.10.016","volume":"126","author":"TA Furukawa","year":"2011","unstructured":"Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophr Res. 2011;126(1\u20133):212\u20139.","journal-title":"Schizophr Res"},{"issue":"1","key":"4036_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","volume":"197","author":"A Pope","year":"2010","unstructured":"Pope A, Adams C, Paton C, Weaver T, Barnes TR. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry. 2010;197(1):67\u201372.","journal-title":"Br J Psychiatry"},{"key":"4036_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-61753-3","volume-title":"Kompendium der Psychiatrischen Pharmakotherapie","author":"O Benkert","year":"2021","unstructured":"Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie: Springer; 2021."},{"issue":"1","key":"4036_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02596485","volume":"4","author":"J Ende","year":"1989","unstructured":"Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients. J Gen Intern Med. 1989;4(1):23\u201330.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"4036_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0447.1994.tb01487.x","volume":"89","author":"M Birchwood","year":"1994","unstructured":"Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994;89(1):62\u20137.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"4036_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1176\/appi.ps.001912012","volume":"64","author":"B O'Donoghue","year":"2013","unstructured":"O'Donoghue B, Roche E, Ranieri VF, Shannon S, Crummey C, Murray J, et al. Service users\u2019 perceptions about their hospital admission elicited by service user-researchers or by clinicians. Psychiatr Serv. 2013;64(5):416\u201322.e1\u20133.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"4036_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pec.2009.09.034","volume":"80","author":"L Kriston","year":"2010","unstructured":"Kriston L, Scholl I, H\u00f6lzel L, Simon D, Loh A, H\u00e4rter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010;80(1):94\u20139.","journal-title":"Patient Educ Couns"},{"issue":"7","key":"4036_CR37","doi-asserted-by":"publisher","first-page":"e0132158","DOI":"10.1371\/journal.pone.0132158","volume":"10","author":"S Rodenburg-Vandenbussche","year":"2015","unstructured":"Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, Scholl I, van der Weijden T, Luyten GP, et al. Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care. PLoS One. 2015;10(7):e0132158.","journal-title":"PLoS One"},{"key":"4036_CR38","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1017\/S2045796020000505","volume":"29","author":"J Hamann","year":"2020","unstructured":"Hamann J, Holzh\u00fcter F, Blakaj S, Becher S, Haller B, Landgrebe M, et al. Implementing shared decision-making on acute psychiatric wards: a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS). Epidemiol Psychiatr Sci. 2020;29:e137.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"2","key":"4036_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pec.2012.03.005","volume":"88","author":"I Scholl","year":"2012","unstructured":"Scholl I, Kriston L, Dirmaier J, Buchholz A, H\u00e4rter M. Development and psychometric properties of the Shared Decision Making Questionnaire--physician version (SDM-Q-Doc). Patient Educ Couns. 2012;88(2):284\u201390.","journal-title":"Patient Educ Couns"},{"issue":"6","key":"4036_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/acps.12526","volume":"133","author":"SD \u00d8stergaard","year":"2016","unstructured":"\u00d8stergaard SD, Lemming OM, Mors O, Correll CU, Bech P. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016;133(6):436\u201344.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"4036_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"1","key":"4036_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41537-021-00168-x","volume":"7","author":"F Hieronymus","year":"2021","unstructured":"Hieronymus F, K\u00f8lb\u00e6k P, Correll CU, \u00d8stergaard SD. Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. NPJ Schizophr. 2021;7(1):41.","journal-title":"NPJ Schizophr"},{"issue":"2","key":"4036_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/acps.12849","volume":"137","author":"CH Lin","year":"2018","unstructured":"Lin CH, Lin HS, Lin SC, Kuo CC, Wang FC, Huang YH. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia. Acta Psychiatr Scand. 2018;137(2):98\u2013108.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"4036_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/schbul\/sbx076","volume":"44","author":"SD \u00d8stergaard","year":"2018","unstructured":"\u00d8stergaard SD, Foldager L, Mors O, Bech P, Correll CU. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophr Bull. 2018;44(2):453\u201362.","journal-title":"Schizophr Bull"},{"key":"4036_CR45","doi-asserted-by":"crossref","unstructured":"Guy W. Clinical global impression. Assessment manual for. Psychopharmacology. 1976:217\u201322.","DOI":"10.1037\/e591322011-001"},{"issue":"4","key":"4036_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4088\/JCP.11m07162","volume":"73","author":"ED Hermes","year":"2012","unstructured":"Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73(4):526\u201332.","journal-title":"J Clin Psychiatry"},{"key":"4036_CR47","doi-asserted-by":"crossref","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987.","DOI":"10.1037\/t64050-000"},{"issue":"4","key":"4036_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla LA, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr Scand. 2000;101(4):323\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"4036_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1026\/0012-1924.53.2.83","volume":"53","author":"E Br\u00e4hler","year":"2007","unstructured":"Br\u00e4hler E, M\u00fchlan H, Albani C, Schmidt S. Teststatistische pr\u00fcfung und normierung der deutschen versionen des EUROHIS-QOL lebensqualit\u00e4t-Index und des WHO-5 wohlbefindens-index. Diagnostica. 2007;53(2):83\u201396.","journal-title":"Diagnostica."},{"issue":"1\u20133","key":"4036_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","volume":"118","author":"MK Vernon","year":"2010","unstructured":"Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso CM, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118(1\u20133):271\u20138.","journal-title":"Schizophr Res"},{"issue":"1","key":"4036_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177\u201383.","journal-title":"Psychol Med"},{"issue":"3","key":"4036_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","volume":"42","author":"K Thompson","year":"2000","unstructured":"Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241\u20137.","journal-title":"Schizophr Res"},{"key":"4036_CR53","first-page":"633","volume-title":"Qualitative inhaltsanalyse","author":"P Mayring","year":"2019","unstructured":"Mayring P, Fenzl T. Qualitative inhaltsanalyse. Handbuch Methoden der empirischen Sozialforschung: Springer; 2019. p. 633\u201348."},{"issue":"2","key":"4036_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00127-016-1327-z","volume":"52","author":"J Hamann","year":"2017","unstructured":"Hamann J, Parchmann A, Sassenberg N, Bronner K, Albus M, Richter A, et al. Training patients with schizophrenia to share decisions with their psychiatrists: a randomized-controlled trial. Soc Psychiatry Psychiatr Epidemiol. 2017;52(2):175\u201382.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"4036_CR55","doi-asserted-by":"crossref","unstructured":"Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 2008;337.","DOI":"10.1136\/bmj.a1655"},{"key":"4036_CR56","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/PPA.S270020","volume":"14","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, O'Sullivan AK, Maher S, Bjorner JB, et al. Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey. Patient Prefer Adherence. 2020;14:2043\u201354.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"4036_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0447.2009.01356.x","volume":"120","author":"J Moncrieff","year":"2009","unstructured":"Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120(2):102\u201311.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"4036_CR58","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2215-0366(21)00243-1","volume":"8","author":"I Bighelli","year":"2021","unstructured":"Bighelli I, Rodolico A, Garc\u00eda-Mieres H, Pitschel-Walz G, Hansen W-P, Schneider-Thoma J, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8(11):969\u201380.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"4036_CR59","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/wps.20577","volume":"17","author":"I Bighelli","year":"2018","unstructured":"Bighelli I, Salanti G, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, et al. Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry. 2018;17(3):316\u201329.","journal-title":"World Psychiatry"},{"key":"4036_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","volume":"111","author":"AA Veroniki","year":"2019","unstructured":"Veroniki AA, Bender R, Glasziou P, Straus SE, Tricco AC. The number needed to treat in pairwise and network meta-analysis and its graphical representation. J Clin Epidemiol. 2019;111:11\u201322.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4036_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jrsm.1428","volume":"12","author":"M Seo","year":"2021","unstructured":"Seo M, Furukawa TA, Veroniki AA, Pillinger T, Tomlinson A, Salanti G, et al. The Kilim plot: A tool for visualizing network meta-analysis results for multiple outcomes. Res Synth Methods. 2021;12(1):86\u201395.","journal-title":"Res Synth Methods"},{"issue":"20","key":"4036_CR62","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1002\/sim.9034","volume":"40","author":"K Chalkou","year":"2021","unstructured":"Chalkou K, Steyerberg E, Egger M, Manca A, Pellegrini F, Salanti G. A two-stage prediction model for heterogeneous effects of treatments. Stat Med. 2021;40(20):4362\u201375.","journal-title":"Stat Med"},{"issue":"2","key":"4036_CR63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/bimj.201900026","volume":"62","author":"D Mavridis","year":"2020","unstructured":"Mavridis D, Porcher R, Nikolakopoulou A, Salanti G, Ravaud P. Extensions of the probabilistic ranking metrics of competing treatments in network meta-analysis to reflect clinically important relative differences on many outcomes. Biom J. 2020;62(2):375\u201385.","journal-title":"Biom J"},{"issue":"5","key":"4036_CR64","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/hex.13313","volume":"24","author":"S Becher","year":"2021","unstructured":"Becher S, Holzh\u00fcter F, Heres S, Hamann J. Barriers and facilitators of shared decision making in acutely ill inpatients with schizophrenia-Qualitative findings from the intervention group of a randomised-controlled trial. Health Expect. 2021;24(5):1737\u201346.","journal-title":"Health Expect"},{"issue":"8","key":"4036_CR65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1176\/ps.2009.60.8.1107","volume":"60","author":"J Hamann","year":"2009","unstructured":"Hamann J, Mendel R, Cohen R, Heres S, Ziegler M, B\u00fchner M, et al. Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. Psychiatr Serv. 2009;60(8):1107\u201312.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"4036_CR66","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1034\/j.1600-0447.2003.00130.x","volume":"107","author":"J Hamann","year":"2003","unstructured":"Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand. 2003;107(6):403\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"4036_CR67","doi-asserted-by":"crossref","unstructured":"Waite F, Langman A, Mulhall S, Glogowska M, Hartmann-Boyce J, Aveyard P, et al. The psychological journey of weight gain in psychosis. Psychol Psychother. 2022.","DOI":"10.1111\/papt.12386"},{"issue":"10092","key":"4036_CR68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","volume":"390","author":"B Djulbegovic","year":"2017","unstructured":"Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415\u201323.","journal-title":"Lancet."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:07:58Z","timestamp":1655471278000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4036"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04036-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the review board of the ethics committee of the Technical University of Munich. This scientific study is aiming to examine whether better information for patients has positive effects on patient-relevant outcomes. The evidence-based information will be presented in a computer-based format. However, the SDM-assistant should only enhance the process of shared-decision making and is not intended to be developed as a medical product or to pursue a commercial interest.Patients meeting inclusion criteria will be asked to provide informed consent (template of the informed consent form available upon request) for study participation, and their capability to provide informed consent will be ensured by trained study staff. Furthermore, we will pay special attention to how many patients decline to participate in the study and ask about the underlying reasons. Participation in the study is voluntary. Consent can be withdrawn at any time, without giving reasons and without disadvantages for further medical care. Should the study be terminated by the physician or patient, the data stored up to this point will continue to be used unless the patient or caregiver explicitly withdraws the release of their patient data. This procedure is pointed out verbally and in the consent form and, in the event of a cancellation, this is recorded accordingly in writing.Data will be saved and exchanged exclusively in pseudonymised forms. Neither the initials nor the date of birth will therefore appear in the encryption code. A study file will be kept for each patient-physician dyad (Case Report Form, CRF), which will be transferred to an electronic study file (eCRF) at the end of the study. After the finalisation of data collection (close out visit) of each patient, copies of both study files, CRF and eCRF, are sent to the managing study centre (AG Patient Orientation and Health Services Research, RDI). The names of the patients and all other confidential information are subject to medical confidentiality and the provisions of the Federal Data Protection Act, i.e., the consent form and personal data remain in the recruiting centre.The transfer of the pseudonymised data to the study management, as well as information on data protection are included in the consent form. In the event of withdrawal of consent, the stored data will be destroyed at the patient\u2019s request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics for approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In the past 3\u2009years Stefan Leucht has received honoraria as a consultant and\/or advisor and\/or for lectures from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Lundbeck, Lundbeck Institute, Merck Sharpp and Dome, Otsuka, Recordati, Rovi, Sanofi Aventis, TEVA, Medichem, Mitshubishi. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"406"}}